Wedbush Begins Coverage on Maze Therapeutics (NASDAQ:MAZE)

Analysts at Wedbush started coverage on shares of Maze Therapeutics (NASDAQ:MAZE - Get Free Report) in a note issued to investors on Tuesday, MarketBeat reports. The brokerage set an "outperform" rating and a $17.00 price target on the stock. Wedbush's price target suggests a potential upside of 12.96% from the company's previous close. Wedbush also issued estimates for Maze Therapeutics' Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.39) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.68) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.70) EPS, FY2026 earnings at ($2.86) EPS, FY2027 earnings at ($2.65) EPS, FY2028 earnings at ($2.71) EPS and FY2029 earnings at ($2.84) EPS.

Separately, Guggenheim restated a "buy" rating and set a $19.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, April 2nd. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $23.50.

Maze Therapeutics Stock Down 3.8%

NASDAQ MAZE traded down $0.59 during trading on Tuesday, hitting $15.05. The company's stock had a trading volume of 127,024 shares, compared to its average volume of 118,689. The business's 50 day moving average is $11.65. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $17.00.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.39).

Institutional Trading of Maze Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. New York State Common Retirement Fund bought a new stake in shares of Maze Therapeutics during the first quarter valued at approximately $25,000. Corebridge Financial Inc. bought a new stake in Maze Therapeutics in the first quarter valued at $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Maze Therapeutics in the first quarter valued at $57,000. Rhumbline Advisers bought a new stake in Maze Therapeutics in the first quarter valued at $80,000. Finally, Deutsche Bank AG bought a new stake in Maze Therapeutics in the first quarter valued at $98,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.